Publications from the Fuhrmann Lab

Gregor Fuhrmann on ORCID 0000-0002-6688-5126 and on Google Scholar

51.     Mehanny M, Boese A, Bornamehr B, Hoppstädter J, Presser V, Kiemer AK, Lehr CM & Fuhrmann G* (2022) Spray-dried Pneumococcal Membrane Vesicles are Promising Candidates for Pulmonary Immunization. International Journal of Pharmaceutics doi.org/10.1016/j.ijpharm.2022.121794     

50.       Drost M, Diamanti E, Fuhrmann K, Goes A, Shams A, Haupenthal J, Koch M, Hirsch AKH & Fuhrmann G* (2022) Bacteriomimetic liposomes improve antibiotic activity of a novel energy-coupling factor transporter inhibitor. Pharmaceutics doi.org/10.3390/pharmaceutics1401000447     

49.       Richter R [...] Fuhrmann G, Pages JM, Lehr CM (2021) An Outer Membrane Vesicle-Based Permeation Assay (OMPA) for Assessing Bacterial Bioavailability. Advanced Healthcare Materials, 2101180

48.       Krämer-Albers EM, Pogge von Strandmann E, Fuhrmann G, Nazarenko I, Giebel B, Pfaffl M (2021) Meeting report of the 4th autumn meeting of the German Society of Extracellular Vesicles (GSEV): cutting edge EV research driven by young scientists. Extracellular Vesicles and Circulating Nucleic Acids doi.org/10.20517/evcna.2021.23  

47.       Fuhrmann G*, Lehr CM & Schiffelers R (2021) Extracellular vesicles in drug delivery and bioengineering. Advanced Drug Delivery Reviews 181, 114073

46.       Mehanny M, Kroniger T, Koch M, Hoppstädter J, Becher D, Kiemer AK, Lehr C-M  &  Fuhrmann G* (2021) Yields and immunomodulatory effects of pneumococcal membrane vesicles differ with the bacterial growth phase. Advanced Healthcare Materials doi.org/10.1002/adhm.202101151

45.       Goes A, Vidakovic L, Drescher K & Fuhrmann G* (2021) Interaction of myxobacteria-derived outer membrane vesicles with biofilms: antiadhesive and antibacterial effects. Nanoscale https://doi.org/10.1039/D1NR02583J 

44.       Trenkenschuh E, Richter M, Heinrich E, Fuhrmann G & Friess W* (2021) Enhancing the Stabilization Potential of Lyophilization for Extracellular Vesicles. Advanced Healthcare Materials doi.org/10.1002/adhm.202100538

43.       Herrmann IK, Wood M & Fuhrmann G* (2021) Extracellular vesicles as next generation drug delivery platform. Nature Nanotechnology, 16:748

42.       Mehanny M, Lehr C-M & Fuhrmann G* (2021) Extracellular vesicles as antigen carriers for novel vaccination avenues. Advanced Drug Delivery Reviews doi.org/10.1016/j.addr.2021.03.016 41.       Pourtalebi Jahromi L & Fuhrmann G* (2021) Bacterial Vesicles as Underexplored Source for Novel Drug Carriers. Advanced Drug Delivery Reviews doi.org/10.1016/j.addr.2021.03.012 40.       Richter M, Vader P & Fuhrmann G* (2021) Approaches to surface engineering of extracellular vesicles. Advanced Drug Delivery Reviews doi.org/10.1016/j.addr.2021.03.020 39.     Trousil J, Aryal S & Fuhrmann G (2021) Biogenic and biomimetic nanocarrier-based interventions: Focus on intracellular infections. Nanomedicine, doi.org/10.2217/nnm-2021-0052

38.     Müller, L Kuhn T, Koch M & Fuhrmann G* (2021) Stimulation of Probiotic Bacteria Induces Release of Membrane Vesicles with Augmented Anti-inflammatory Activity. ACS Applied Bio Materials, doi.org/10.1021/acsabm.0c01136

37.     Kuhn T, Koch M & Fuhrmann G* (2020) Probiomimetics—Novel Lactobacillus‐Mimicking Microparticles Show Anti‐Inflammatory and Barrier‐Protecting Effects in Gastrointestinal Models. Small, doi.org/10.1002/smll.202003158

36.     Whitworth DE, Jurkevitch E, Perez J, Fuhrmann G & Koval SF (2020) Mechanisms of Prokaryotic Predation. Frontiers in Microbiology doi:10.3389/fmicb.2020.02071 35.     Fuhrmann G* (2020) Diffusion and transport of extracellular vesicles. Nature Nanotechnology, doi: 10.1038/s41565-020-0651-3

34. Zivko C, Fuhrmann G* & Luciani P* (2020) Liver-derived extracellular vesicles: a cell-by-cell overview to isolation and characterization. Biochimica et Biophysica Acta, doi: 10.1016/j.bbagen.2020.129559

33. Mehanny M, Koch M, Lehr C-M & Fuhrmann G* (2020) Streptococcal extracellular membrane vesicles are rapidly internalized by immune cells and alter their cytokine release. Frontiers in Immunology, 11:80

32. Goes A, Lapuhs P, Kuhn T, Schulz E [...] & Fuhrmann G* (2020) Myxobacteria-derived outer membrane vesicles: potential applicability against intracellular infections. Cells, 9:194

31. Montefusco-Pereira C, Formicola B, Goes A [...] Fuhrmann G, Caneva E, Nicotra F, Lehr C-M (2020) Coupling quaternary ammonium surfactants to the surface of liposomes improves both antibacterial efficacy and host cell biocompatibility. European Journal of Pharmacy and Biopharmacy, 149:12

30. Schulz E, Karagiannis A & Fuhrmann G* (2020) Hot EVs – how temperature affects extracellular vesicles. European Journal of Pharmacy and Biopharmacy, 146:55

29. Woith E, Fuhrmann G* & Melzig MF* (2019) Extracellular Vesicles – Connecting Kingdoms. International Journal of Molecular Sciences, 20:5965

28. Hoppstädter J, Dembek A, Barghash A, Fecher-Trost C, Fuhrmann G, Koch M, Kraegeloh A, Huwer H, Kiemer AK (2019) Toll-like receptor 2 release by macrophages: an anti-inflammatory program induced by glucocorticoids and lipopolysaccharide. Frontiers in Immunology 10:1634

27.     Richter M, Fuhrmann K & Fuhrmann G* (2019) Evaluation of the storage stability of extracellular vesicles. Journal of Visualized Experiments, 147:e59584

See the full video protocol here.

26.    Thery C, Witwer K […] Fuhrmann G et al. (2019) Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV): an update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 8:1535750

25.    Schulz E, Goes A, Panter F, Koch M, Garcia R, Müller R, Fuhrmann K & Fuhrmann G* (2018) Biocompatible bacteria-derived vesicles show inherent antimicrobial activity. Journal of Controlled Release 290:46

24.     Fuhrmann G* (2018) Luminal coating of the intestine. Nature Materials  17:754

23.    Frank J, Richter M, De Rossi C, Lehr CM, Fuhrmann K & Fuhrmann G* (2018) Extracellular vesicles protect glucuronidase model enzyme during freeze-drying. Scientific Reports  8:12377

22.    Goes A & Fuhrmann G* (2018) Biogenic and biomimetic carriers as versatile transporters to treat bacterial infections. ACS Infect Diseases  4:881

21.     Fuhrmann G* (2018) Experimental therapies for coeliac diseases. Pharmakon  6(2):44

20.     Fuhrmann G, Chandrawati R et al. (2018) Engineering extracellular vesicles with the tools of enzyme prodrug therapy Advanced Materials  30:1706616

This work was featured as back cover in Advanced Materials

19.     Fuhrmann K & Fuhrmann G* (2017) Recent advances in oral delivery of macromolecular drugs and benefits of polymer conjugation Current Opinion in Colloid & Interface Science  31:67 (*GF corresponding author)

18.     Frank J & Fuhrmann G* (2017) Best before - lyophilisation as novel storage alternative for extracellular vesicles Journal of Extracellular Vesicles  6:sup1, DOI: 10.1080/20013078.2017.1310414 (*GF corresponding author)

17.   Fuhrmann G*, Neuer AL & Herrmann IK (2017) Extracellular vesicles – a promising avenue for the detection and treatment of infectious diseases? European Journal of Pharmaceutics and Biopharmaceutics 118:56 (*GF sole corresponding author)

16.   Fuhrmann G* & Stevens MM (2016) Stability of extracellular vesicles during lyophilisation – implications for their pharmaceutical use. Journal of Extracellular Vesicles 5: 30924-30940 (*GF co-corresponding author)

15.   Whittaker T, Fuhrmann G & Stevens MM (2016) Purifying extracellular vesicles by size exclusion: give it a little longer. Journal of Extracellular Vesicles 5: 30924-30940

14.   Liu M, Fuhrmann G, Johansen P, Leroux J & Gauthier MA (2016) "Bio-hybrid" therapeutics. Frontiers in Bioengineering and Biotechnology doi: 10.3389/conf.FBIOE.2016.01.00919

13.   Santos L, Fuhrmann G, Juenet M, Amdursky N, Horejs C-M, Campagnolo P & Stevens MM (2015) Extracellular stiffness modulates the expression of functional proteins and growth factors in endothelial cells. Advanced Healthcare Materials 4: 2056-2063

12.   Fuhrmann G1, Herrmann IK1 & Stevens MM (2015) Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today 10: 397-409 (1GF and IH with equal contribution)

11.  Fuhrmann G*, Serio A, Mazo M, Nair R & Stevens MM (2015), Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. Journal of Controlled Release 205: 35-44 (*GF co-corresponding author)

10.   Fuhrmann G & Leroux J-C (2014) Improving the stability and activity of oral therapeutic enzymes - recent advances and perspectives. Pharmaceutical Research  31:1099-1105

9.    Fuhrmann G, Gauthier MA & Leroux J-C (2013) Polymer-enzyme conjugates for oral drug delivery applications. Chimia  67:685-686

8.   Fuhrmann G, Grotzky A, Lukic R, Matoori S, Luciani P, Zhang B, Yu H, Walde P, Schlüter AD, Gauthier MA & Leroux J-C (2013) Sustained gastrointestinal activity of dendronized polymer-enzyme conjugates. Nature Chemistry 5: 582–589.

This work was highlighted in Nature Chemistry News and Views (2013, 5:557–558)

7.   Matoori S, Fuhrmann G & Leroux J-C (2012) Celiac disease: a challenging disease for pharmaceutical scientists. Pharmaceutical Research 30:619-626

6.   Pinier M, Fuhrmann G, Galipeau H, Rivard H, Murray JA, David CS, Tuckova L, Drasarova H, Leroux J-C & Verdu EF (2012) The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 142: 316-325.e12.

5.   Matoori S, Fuhrmann G, Jessica D Schulz & Leroux J-C (2012) Gluten binden und spalten - neue adjuvante Therapiemöglichkeiten für Zöliakie. Swiss Medical Forum 12:716–717

4.   Fuhrmann G & Leroux J-C (2011) In vivo fluorescence imaging of exogenous enzyme activity in the gastrointestinal tract. Proceedings of the National Academy of Sciences USA 108:9032-9037.

This work was highlighted in numerous daily newspapers in Germany, Switzerland and Austria, in coeliac disease fora, and in ETH Life (August 2011).

3.    Fuhrmann G & Leroux J-C (2010) In vitro evaluation of the stability of proline-specific endopeptidases under simulated gastrointestinal conditions. Journal of Controlled Release 148:e37-e39.

2.    Pinier M1, Fuhrmann G1, Verdu E, & Leroux J-C (2010) Prevention measures and exploratory pharmacological treatments of celiac disease. American Journal of Gastroenterology 105:2551-2561 (1MP and GF with equal contribution)

1.     Bastiat G, Plourde F, Motulsky A, Furtos A, Dumont Y, Quirion R, Fuhrmann G & Leroux  J-C (2010) Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease. Biomaterials 31:6031-6038

Book chapters

1.      Lapuhs P & Fuhrmann G* (2019) Engineering strategies for oral therapeutic enzymes. Advances in Experimental Medicine and Biology (Springer Nature). In: Labour N (Ed.) Therapeutic Enzymes: Function and Clinical Implications, 151-172, doi.org/10.1007/978-981-13-7709-9